麻豆精选

• Postgraduate Certificate in Higher Education Teaching and Learning, 2013
• PhD in Pharmaceutics, Queen’s University of Belfast, 2008
• MSc in Biomolecular Structure and Function, Queen’s University of Belfast, 2005
• BSc in Applied Biochemical Sciences, University of Ulster, 2003

Dr McConville completed his PhD and postdoctoral training in the School of Pharmacy at the Queen’s University of Belfast on the formulation and drug delivery of HIV microbicides.  He used innovative engineering techniques such as hot melt extrusion, injection moulding and 3D printing to manufacture novel vaginal dosage forms such as vaginal rings and tablets.  When he took up his first independent research post he decided to use these innovative techniques to manufacture implantable devices for the localised treatment of hard-to-treat cancers such as brain tumours and pancreatic cancer.

His current independent and collaborative research is focused on the use of cutting-edge pharmaceutical engineering technologies such as hot melt extrusion, injection moulding, 3D printing, microfluidics etc. to manufacture novel implantable drug delivery devices and nanoparticles for the localised and personalised treatment of cancers.

His research has resulted in the development of an implantable device for the local delivery of chemotherapy to the brain (ChemoSeed^®).  He founded Extruded Pharmaceuticals Ltd (EPL) in 2016 and joined the Board as Chief Scientific Officer (CSO) to take ChemoSeed^® into the clinic and onto commercialisation. ChemoSeed^® is currently being utilised by several pharmaceutical companies for the sustained delivery of their leading drug candidates.

In 2022 he was appointed as Translational Lead for the Precision health Technologies Accelerator (PHTA) to take innovative technologies from proof-of-concept and feasibility through clinical trials and onto commercial registration.  He is responsible for establishing the translational and commercialisation pathway for the technology, identify academics, clinicians, industry partners etc. needed to advance the technology onto commercialisation and then build and lead the team to ensure the translational and commercialisation pathway is followed and goals and targets achieved on time.

In 2023 Dr McConville was appointed as Director of Research for the Institute of Clinical Sciences and will lead the REF2028 submission for Unit of Assessment 3.

• MPharm

Since joining Birmingham Dr McConville has successfully supervised 12 PhD students and 10 MRes students.

Dr McConville is further interested in supervising doctoral research students in the following areas:

• Implantable devices for localised treatment of brain tumours
• 3D printing of solid dosage forms
• Nanotechnology
• Solubility enhancement

Dr McConville has research and doctoral supervision interests in the fields of drug delivery, solubility enhancement, implantable devices, and nanotechnology.  Dr McConville’s research group interests include:

Current projects

• Implantable devices for the localised treatment of hard-to-treat cancers.
• 3D printing of solid dosage forms
• Manufacture of personalised dosage forms
• Nanoparticles
• Solubility enhancement

• External examiner for a number of PhD programmes including Aston University, Ulster University, Queens University Belfast, Athlone Institute of Technology, the University of Queensland, the University of Nottingham and Imperial College London.
• Expert Panel Member Tessa Jowell Brain Tumour Research Novel Therapeutics Accelerator (BTR-NTA) programme
• Translational Lead for the PHTA Ltd
• Consultant for several pharmaceutical companies
• EPSRC Peer Review College Member
• Member of the EPSRC: Health Technologies Investigator-Led review panel